Company Profile
Avenue Therapeutics Stock Price, News & Analysis
- Ticker:
- ATXI
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.30 USD (0.00%)
Close
Last updated: August 5, 2026
—
Market cap
Why the stock is moving
Current closing-price context is not available for ATXI.
Company overview
Business overview
Avenue Therapeutics is a specialty pharmaceutical company focused on acute and hospital-based pain management. Its story revolves around trying to bring differentiated pain treatments into controlled clinical settings.
Geographic Base and Sector Classification
Avenue Therapeutics is headquartered in the United States and listed on NASDAQ. It sits in specialty pharma and acute-care pain management.
Business Model Characteristics
The company depends on clinical and regulatory progress, commercial strategy, and the ability to sustain a narrow product focus. Investors track trial updates, development milestones, and capital runway.
Position Within the Biotechnology Landscape
Avenue occupies a small acute-pain niche within specialty pharma. The stock tends to move on regulatory news and the market's view of the company’s ability to commercialize in a difficult category.
Future catalysts
Avenue Therapeutics is largely a legacy and closeout story now, so the catalysts are any strategic or asset-resolution update rather than a live pipeline event. The market is mainly focused on residual value.
Recent news
- 01
- 02
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
Source: Avenue Therapeutics
- 03
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Source: Avenue Therapeutics
- 04
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit
Source: Avenue Therapeutics
- 05
Avenue Therapeutics to Participate in Upcoming Investor Conferences
Source: Avenue Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Avenue Therapeutics (ATXI)?
Avenue Therapeutics (ATXI) most recently closed at 0.30 USD, a 0.00% move versus the previous session.
What does Avenue Therapeutics do?
Avenue Therapeutics is a specialty pharmaceutical company focused on acute and hospital-based pain management. Its story revolves around trying to bring differentiated pain treatments into controlled clinical settings.
On which exchange is ATXI stock listed?
Avenue Therapeutics (ATXI) is associated with NASDAQ, United States, Biopharma.
What is Avenue?
Avenue Therapeutics is largely a legacy and closeout story now, so the catalysts are any strategic or asset-resolution update rather than a live pipeline event.
Which conditions is Avenue Therapeutics targeting with Avenue?
Avenue Therapeutics is largely a legacy and closeout story now, so the catalysts are any strategic or asset-resolution update rather than a live pipeline event.
How does Avenue Therapeutics describe recent progress with Avenue?
Avenue Therapeutics is largely a legacy and closeout story now, so the catalysts are any strategic or asset-resolution update rather than a live pipeline event.
What is Therapeutics?
Avenue Therapeutics is a specialty pharmaceutical company focused on acute and hospital-based pain management.
What should investors watch for with Therapeutics?
Avenue Therapeutics is largely a legacy and closeout story now, so the catalysts are any strategic or asset-resolution update rather than a live pipeline event.